What Is the New 2-DG Drug by DRDO and How Does It Help COVID-19 Patients?

Mumbai Live19 May, 2021News

With India currently going through a challenging second phase of the coronavirus, a drug known as 2-DG (2-deoxy-D-glucose) will soon reach patients across the country to boost recovery and also reduce oxygen dependence among critical patients. This drug has been jointly developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), which is a lab belonging to the Defence Research and Development Organisation (DRDO), along with Dr Reddy?s Laboratories, Hyderabad. The Drugs Controller General of India (DCGI) has approved this drug for emergency use among moderate to severe COVID-19 patients as an adjunct therapy.